RTTNews BiotechDoubao · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 15:06:19(美东 03:06)·⟳ 抓取 15:06:33 +14s·⚡ 决策 10-19 16:33:15 +1h26m·8.0 天前
GSK公布B7-H3 ADC药物Ris-Rez（HS-20093）复发小细胞肺癌全球首批Ib期数据，8mg/kg剂量ORR达61%
对GSK而言Ib期早期数据相对其千亿英镑级体量不具materiality；对翰森制药而言最强证据（中国III期OS阳性）已在一个多月前WCLC公布，本次全球Ib期ORR数据只是确认性增量，无新生存终点、无明确里程碑现金流入，短线风险收益不足。
📄 原文RTTNews Biotech↗ 原文
GSK Reveals Positive Early Data For Ris-Rez In Extensive-stage Small Cell Lung Cancer
British drug major GSK plc (GSK,GSK.L) announced Monday the first global data for risvutatug rezetecan (Ris-Rez), its i…
不做 葛兰素史克（GSK.US）
超大市值药企，单一在研ADC的Ib期ORR数据不具materiality，盘前几乎平开（-0.04%）且无量，属典型软催化，无短线edge；不做多也无任何利空可做空
不做 翰森制药（03692.HK）
同一资产决定性的中国III期OS阳性已于2026-09-13 WCLC公布并被卖方覆盖，本次全球Ib期ORR仅为小样本确认性增量、无生存终点、无明确里程碑现金流入；港股下一交易时段为10月20日开盘，追高风险收益不足，且数据本身积极、不构成做空理由
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Ris-Rez复发SCLC首批全球Ib期数据积极（8mg/kg ORR 61%），但属早期小样本确认性数据：GSK体量巨大、催化软且盘前无反应；翰森制药的关键III期OS利好已于9月WCLC释放并定价，本次增量不足以驱动可交易行情，双向均不做。
消息传播链
- 报道GSK公布Ris-Rez在ES-SCLC的首批全球Ib期数据（8mg/kg ORR 61%），将在ESMO 2026壁报展示；未获GSK官网IR原文链接，按转述GSK通稿处理市场反应:GSK.US盘前约49.49美元，较前收49.51基本持平（-0.04%），盘前量极低，市场未给出显著正反馈
关键理由
- Ib期ORR数据积极且安全性可控，支持GSK加速海外开发，方向上对GSK与翰森均为正面
- 但决定性证据（翰森ARTEMIS-008 III期OS显著获益）已于2026-09-13 WCLC公布，本次为同一资产的低级别增量确认
主要风险
- Ib期可评估样本量小、仅ORR终点，若壁报披露的DOR/PFS或安全性细节不及预期，可能反向波动
- 若市场将其解读为GSK推进全球注册性研究、并触发预期外里程碑或BD重估，翰森周二开盘存在小幅跳空高开风险（踏空而非亏损风险）
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
未检索到本资产新的安全性/监管利空；但Ib期仅有ORR、样本小、剂量依赖明显（32%→61%），且未发现本次数据触发里程碑付款的证据，削弱短线做多理由
检索:HS-20093 Ris-Rez 安全性 剂量 毒性 延迟 里程碑 负面 原文 ↗ - 做多前查反向 · 来源 futu行情 · 日期 2026-10-16 · 影响 weakens
翰森03692.HK近20日-6.8%、距60日高点-13.9%，9月13日WCLC强数据后资金整体兑现，提示会议数据类催化追高胜率低
检索:翰森制药 III期 WCLC 后 股价 回调 利好兑现
先例如何影响了这次决策
对本次决策的影响:先例不足叠加自身前序证据，支持对两条腿均给AVOID，而非用小仓试探
方向:未构建足量干净先例：同一资产最接近的可比节点为2026-09-13翰森III期OS公布，但属公司自身前序事件且时间在回放窗口内，不宜作为外部对齐先例
涨幅量级:缺乏同市场、同相位（海外Ib期数据读出）高相似先例校准幅度，不足以支持定量止盈止损
形态:GSK盘前对Ib期数据无反应（-0.04%）本身已印证大药企早期数据弹性低；翰森在III期利好后20日仍-6.8%，提示会议数据兑现后资金偏sell-the-news
工具执行结果 · 成功 5 · 降级 0 · 失败 2 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 14 ms
{"result": "search_processed_events:agent query=`gsk risvutatug rezetecan ris-rez b7-h3 adc es-sclc phase ib embold pantumoir-101 orr 61% | risvutatug rezetecan esmo 2026 poster gsk hansoh | 翰森制药 hs-20089 b7-h3 adc gsk 授权 小细胞肺癌 i`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - web_search 成功 doubao_search · 1,644 ms
豆包搜索结果（原始查询:GSK Hansoh B7-H3 ADC risvutatug rezetecan HS-20089 license deal upfront milestones；API SearchType:web） - web_search 成功 doubao_search · 1,638 ms
豆包搜索结果（原始查询:翰森制药 HS-20089 小细胞肺癌 III期 总生存 结果 2026；API SearchType:web） - kb_search 失败 stock_tools HTTP · 63 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - stock_quote 成功 stock_tools HTTP · 52 ms
{ - stock_quote 失败 stock_tools HTTP · 111 ms
行情服务暂不可用；本次无法核验该标的价格和可执行条件。请基于其余证据继续判断并明确标注行情降级；不得仅因工具故障自动给出 AVOID 或 ENTER，也不得编造价位。 - stock_quote 成功 stock_tools HTTP · 60 ms
{
原文全文
展开原文 · 2,128 字
British drug major GSK plc (GSK,GSK.L) announced Monday the first global data for risvutatug rezetecan (Ris-Rez), its investigational B7-H3-targeted antibody-drug conjugate (ADC), in patients with relapsed extensive-stage small cell lung cancer or ES-SCLC.
The company noted that the results from the phase Ib dose-optimisation portion of the EMBOLD PanTumour-101 trial showed positive anti-tumour activity and a manageable safety profile. The data adds to recently reported positive phase III data in patients with SCLC in China.
Ris-Rez is a novel investigational antibody-drug conjugate targeting the B7-H3 protein, which is highly expressed in more than 10 solid tumour types.
EMBOLD PanTumour-101 (NCT06551142), a global, open-label phase Ia/b study, evaluates the safety, tolerability and clinical activity of Ris-Rez monotherapy in adult patients with advanced or metastatic solid tumours.
In the trial, Ris-Rez achieved a confirmed objective response rate or ORR of 61% among evaluable patients at the 8 mg/kg dose, compared with 32% at the 6 mg/kg dose.
The company plans to present the findings in a poster session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
Hesham Abdullah, Senior Vice President, Global Head of Oncology, R&D, GSK said, "Today's first global data for Ris-Rez build on the statistically significant overall survival benefit recently reported in Hansoh's pivotal Chinese trial. As the data for Ris-Rez continues to grow, we remain focused on accelerating development in extensive-stage small cell lung cancer, where patients often relapse quickly and urgently need more treatment options."
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
The company noted that the results from the phase Ib dose-optimisation portion of the EMBOLD PanTumour-101 trial showed positive anti-tumour activity and a manageable safety profile. The data adds to recently reported positive phase III data in patients with SCLC in China.
Ris-Rez is a novel investigational antibody-drug conjugate targeting the B7-H3 protein, which is highly expressed in more than 10 solid tumour types.
EMBOLD PanTumour-101 (NCT06551142), a global, open-label phase Ia/b study, evaluates the safety, tolerability and clinical activity of Ris-Rez monotherapy in adult patients with advanced or metastatic solid tumours.
In the trial, Ris-Rez achieved a confirmed objective response rate or ORR of 61% among evaluable patients at the 8 mg/kg dose, compared with 32% at the 6 mg/kg dose.
The company plans to present the findings in a poster session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
Hesham Abdullah, Senior Vice President, Global Head of Oncology, R&D, GSK said, "Today's first global data for Ris-Rez build on the statistically significant overall survival benefit recently reported in Hansoh's pivotal Chinese trial. As the data for Ris-Rez continues to grow, we remain focused on accelerating development in extensive-stage small cell lung cancer, where patients often relapse quickly and urgently need more treatment options."
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ada8c9b473· 2026-10-19 16:33 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前